Target Wise and Pound Foolish: A simple technique to evaluate the trade-off between clinical benefit and economic burden of monoclonal antibodies

ConclusionThe “common currency” of NNT provides a concise, clinically relevant approach for framing the debate between individual benefit and public health priorities. Some monoclonal antibodies for some hematology/oncology indications may not meet reasonable thresholds for widespread use.
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research